Products
Online Inquiry
ZLN024
Cat. No.:
0225LY-1020
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
ZLN024 serves as an allosteric AMPK activator that stimulates active heterotrimers and specific inactive α1 subunit truncations, though it does not affect α1 (1-312).
Synonym:
723249-01-2; ZLN-024; ZLN 024; 2-[2-(2-bromo-4-methylphenoxy)ethylsulfanyl]pyrimidine; 2-(2-(2-bromo-4-methylphenoxy)ethylthio)pyrimidine; 2-((2-(2-Bromo-4-methylphenoxy)ethyl)thio)pyrimidine; 2-[[2-(2-Bromo-4-methylphenoxy)ethyl]thio]-pyrimidine; 2-{[2-(2-bromo-4-methylphenoxy)ethyl]sulfanyl}pyrimidine; 2-bromo-4-methylphenyl 2-(2-pyrimidinylsulfanyl)ethyl ether
CAS No.:
723249-01-2
Compound CID:
1825716
Formula:
C13H13BrN2OS
Formula Weight:
325.22
Specification
Targets&IC50:
AMPK α2β2γ1: 0.13 μM (EC50); AMPK α1β1γ1: 0.42 μM (EC50); AMPK α1β2γ1: 1.1 µM; AMPK α2β1γ1: 0.95 μM (EC50)
Relative Density:
1.49 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ZLN024 can be used in diabetes research to investigate the systemic effects of potent AMPK activation on insulin sensitivity.
Library Information
Target:
AMPK α1β1γ1; AMPK α1β2γ1; AMPK α2β1γ1; AMPK α2β2γ1
Receptor:
Serine/Threonine Protein Kinase
Pathways:
PI3K/Akt/mTOR signaling; Chromatin/Epigenetic
Plate Number:
AOCL-14
Plate Location:
b3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 153.74 mM
